Trump Slaps 100% Tariff on Patented Drug Imports, Revamps Metal Duties

The United States has announced a 100% tariff on imports of patented pharmaceutical products from countries, including India, that lack specific reshoring or pricing agreements with US agencies. Generic medicines are currently exempt but face future review if production does not shift back to the US. Concurrently, the administration simplified tariffs on goods containing steel, aluminum, or copper, applying a flat 25% duty if metal content exceeds 15% of the product's weight. These sweeping trade measures, signed by President Trump, coincide with the anniversary of his major global tariff plan.

Key Points: US 100% Tariff on Patented Drugs, New Metal Duty Rules

  • 100% tariff on patented drug imports
  • Generics exempt for now
  • Simplified 25% tariff on high-metal-content goods
  • Five country groups get lower rates
  • Measures take effect July 31 & Sept 29
2 min read

Trump imposes 100% tariff on patented drug imports; revises metal duties

US imposes 100% tariff on patented drug imports from nations like India without reshoring deals, and simplifies tariffs on steel, aluminum, and copper.

"100% tariff is on patented products. - Senior White House Official"

By Reena Bhardwaj, Washington, DC, April 3

The United States has announced sweeping new trade measures targeting patented pharmaceutical imports and metals, as President Donald Trump signed two significant executive actions.

Under the new framework on Thursday, a 100% tariff will apply to patented drug imports from countries, including India, that have neither signed a reshoring agreement with the US Commerce Department nor a Most Favoured Nation (MFN) pricing deal with the Department of Health and Human Services (HHS).

A senior White House official said the measure was designed to reduce America's dependence on foreign nations for essential medicines. The official further told ANI, "100% tariff is on patented products. Any patented drug imports from India made by companies that do not get approved for a reshoring plan will be subject to a 100% tariff."

Generic medicines are currently exempt, though officials cautioned this could change if the generics industry does not move production back to the United States swiftly enough.

"Generics, which are the majority of Indian pharma exports, are exempt from tariffs, but the Commerce Department will evaluate the state of generics reshoring and re-evaluate generics tariffs accordingly," the official further told ANI.

The tariff comes into effect on July 31 for larger companies and September 29 for smaller ones.

Five country groupings have been offered preferential rates. The European Union, Japan, South Korea, and Switzerland will each face a 15% tariff. The United Kingdom, whose major pharmaceutical companies, including GSK, have already signed reshoring and MFN agreements, will face a lower rate of 10%, with the expectation that this could eventually reach zero.

The administration also announced changes to how existing tariffs on steel, aluminium, and copper are calculated, a revision that will have direct implications for Indian metal exporters.

For products that contain these metals, the rules have been simplified. Goods where the metal content accounts for less than 15% of the product's weight will attract no separate metals tariff, facing only the standard country-level duty. Where metal content exceeds 15% by weight, a flat 25% tariff will apply to the full product value, irrespective of the precise metal composition.

Thursday's announcements coincide with the first anniversary of Trump's so-called "Liberation Day," the moment last year when the president unveiled a sweeping global tariff plan that sent shockwaves through international markets and fundamentally reshaped the landscape of world trade.

- ANI

Share this article:

Reader Comments

A
Arjun K
The timing is terrible for our economy. First the metal duties, now this. While I understand any country's right to protect its own industry, a 100% tariff is punitive. Hope our trade ministers have a solid plan B.
R
Rohit P
At least generics are exempt for now. That's a relief. But the pressure to "reshore" is clear. Maybe this is the push Indian companies needed to focus more on our domestic market and other regions like Africa and Latin America.
S
Sarah B
Working in the pharma sector in Hyderabad, this news has created a lot of anxiety. The 15% rule for metal content in products is also very tricky for engineering exports. A double whammy.
V
Vikram M
Look at the country groupings. EU, Japan at 15%. UK at 10% aiming for zero. We are not even in that conversation. It shows a lack of strong trade diplomacy on our part over the years. We need to build better alliances.
K
Karthik V
This is a wake-up call for 'Atmanirbhar Bharat'. We must reduce our own dependence on the US market and invest heavily in R&D for new drugs. Let's turn this challenge into an opportunity. 💪
M
Meera T
While the action is tough,

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50